FISIOLOGÍA Y FARMACOLOGÍA
Departamento
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (19)
2022
-
Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia
Hepatology, Vol. 76, Núm. 5, pp. 1259-1274
-
Impact of Liver Inflammation on Bile Acid Side Chain Shortening and Amidation
Cells, Vol. 11, Núm. 24
-
Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)
Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734
-
RICORS2040: The need for collaborative research in chronic kidney disease
Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387
-
Urinary KIM-1 Correlates with the Subclinical Sequelae of Tubular Damage Persisting after the Apparent Functional Recovery from Intrinsic Acute Kidney Injury
Biomedicines, Vol. 10, Núm. 5
2021
-
Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury
JHEP Reports, Vol. 3, Núm. 3
-
Management of acquired hemophilia A: results from the Spanish registry
Blood Advances, Vol. 5, Núm. 19, pp. 3821-3829
-
Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis
Molecular Metabolism, Vol. 53
-
Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma
Cells, Vol. 10, Núm. 3
-
Urinary Plasminogen Activator Inhibitor-1: A Biomarker of Acute Tubular Injury
American Journal of Nephrology, Vol. 52, Núm. 9, pp. 714-724
2020
-
Combined use of GM2AP and TCP1-eta urinary levels predicts recovery from intrinsic acute kidney injury
Scientific Reports, Vol. 10, Núm. 1
-
Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-pembresid clinical trial
Cancers, Vol. 12, Núm. 12, pp. 1-13
-
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
Haematologica
-
Protein translation inhibition is involved in the activity of the pan-pim kinase inhibitor pim447 in combination with pomalidomide-dexamethasone in multiple myeloma
Cancers, Vol. 12, Núm. 10, pp. 1-20
-
Urinary TCP1-eta: A Cortical Damage Marker for the Pathophysiological Diagnosis and Prognosis of Acute Kidney Injury
Toxicological Sciences, Vol. 174, Núm. 1, pp. 3-15
2019
-
Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
Cells, Vol. 8, Núm. 11
-
Drug-induced thrombotic microangiopathy during maintenance treatment in a patient with multiple myeloma
HemaSphere, Vol. 3, Núm. 3
-
Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant
Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1825-1831
2016
-
Assessment of Kidney Graft Function Evolution Measured by Creatinine and Cystatin C
Transplantation Proceedings, Vol. 48, Núm. 9, pp. 2913-2916